Elisa Agostinetto
Enriched profileMedical oncologist and breast cancer researcher · Université Libre de Bruxelles
Elisa Agostinetto is Medical oncologist and breast cancer researcher at Université Libre de Bruxelles. OpenAlex indexes 194 publications with 2,992 citations (h-index 28).
Data verified 8 Nov 2026
Overview
Updated 8 Nov 2026
Elisa Agostinetto is Medical oncologist and breast cancer researcher at Université Libre de Bruxelles (Faculté de Médecine). The public record shows 194 publications with 2,992 citations (h-index 28), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, BRCA gene mutations in cancer.
- Most recent indexed publication: 2026 · Journal of the National Cancer Institute
- Top research focus: Breast Cancer Treatment Studies
Generated from the cited public record · current as of 8 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 28 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 59.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →
Clinical trials
We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 8 Nov 2026
43 congress contributions (2017–2026) across AACR, ASCO, ESHRE Annual Meeting, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 8 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
Journal of the National Cancer Institute
Clinical Trial2026 - Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.
Nature communications
Clinical Trial2025 - Breastfeeding after breast cancer in young BRCA carriers.
Journal of the National Cancer Institute
Article2025
Congress posts on X
Post links from an X account tied to this person through reviewed identity evidence.
Listed under ESMO 2026
Listed under ESMO 2026
Listed under ESMO 2026
These links cover selected congress pages. They do not establish attendance or a complete posting history. Post availability may change.
Online presence
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/ElisaAgostinett
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 8 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Doctorat en sciences médicales (doctorate in medical sciences)
ULB, thesis "Immunotherapy in Breast Cancer", public defence 22 April 2026
2026 - Medical degree
University of Udine (Italy), per third-party profile
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗
Editorial & leadership roles
journal and society appointments- Member
European Society for Medical Oncology (ESMO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Member
American Society of Clinical Oncology (ASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Member
Belgian Society of Medical Oncology (BSMO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Young investigator
EORTC Breast Cancer Working Group
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practiceupdate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchoncology.com ↗
- Early Investigator Award
San Antonio Breast Cancer Symposium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →new.oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →inventaire.ulb.be ↗
- Institut Jules Bordet (Brussels)
breast cancer researcher and medical oncologist
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchoncology.com ↗
Media & interviews
press, podcasts and appearances- Audio Journal of Oncology episode: EBCC 2026
circulating tumor DNA after neoadjuvant therapy in early breast cancer
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →next.audiomedica.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →new.oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Antoine Bondue
Université Libre de Bruxelles
Jean‐Louis Vincent
Université Libre de Bruxelles
Martine J Piccart
Université Libre de Bruxelles
Christos P. Sotiriou
Université Libre de Bruxelles
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope